Antibiotice S.A. Logo

Antibiotice S.A.

Develops and manufactures generic medicines and APIs, specializing in anti-infectives.

ATB | RO

Overview

Corporate Details

ISIN(s):
ROATBIACNOR9
LEI:
315700P5G4O1L6GLMS02
Country:
Romania
Address:
VALEA LUPULUI, 707410 IAȘI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Antibiotice S.A. is a pharmaceutical company specializing in the development and manufacturing of generic medicines. With a history of over 65 years, the company produces a diverse portfolio of products for human use, including finished dosage forms and Active Pharmaceutical Ingredients (APIs). Its offerings have a strong focus on anti-infectives, such as penicillin-derived products. The company operates eight GMP-certified manufacturing lines and holds U.S. FDA approvals for key products, including Nystatin (API), Ampicillin for injection, and Nafcillin. Antibiotice is committed to making valuable medicines accessible and affordable for patients and healthcare professionals, driven by continuous investment in research, quality, and the modernization of its manufacturing technologies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 15:37
ISS
Raport curent de informare a investitorilor
Romanian 1.0 MB
2025-11-07 07:37
Report Publication Announcement
Raport curent de informare a investitorilor
Romanian 546.9 KB
2025-11-06 12:52
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 643.5 KB
2025-11-06 12:49
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 1.0 MB
2025-11-05 10:20
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 291.4 KB
2025-10-03 11:39
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-10-03 11:38
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 1.7 MB
2025-10-01 12:53
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 2.4 MB
2025-09-23 08:35
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-09-17 15:12
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 949.8 KB
2025-09-04 12:29
Notice of Dividend Amount
Plata dividend - RC17
Romanian 2.1 MB
2025-08-13 12:27
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-08-06 12:40
Report Publication Announcement
Raport curent de informare a investitorilor
Romanian 137.7 KB
2025-07-24 12:07
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.6 MB
2025-07-09 12:28
Board/Management Information
Raport curent de informare a investitorilor
Romanian 491.4 KB

Automate Your Workflow. Get a real-time feed of all Antibiotice S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Antibiotice S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Antibiotice S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT

Talk to a Data Expert

Have a question? We'll get back to you promptly.